Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is a study of GAP-134, an antiarrhythmic di-peptide. This study will provide an initial
assessment of the safety, tolerability, and pharmacokinetics (PK) of GAP-134 after
administration of ascending single intravenous (IV) doses to healthy Japanese male subjects.